Globus Medical, Inc. (GMED) SEC Filings & Earnings Calls

GAAP net income decline due to prior year bargain purchase gain

“GAAP net income for the quarter was $151.6 million, a decrease of 25.3% over the same period in the prior year” · word for word

Enabling Technologies revenue decline

“Enabling Technologies 26,072 35,160” · word for word

Potential dilution from increased authorized shares, but standard for equity compensation.

“increase the number of shares authorized thereunder by 1,000,000” · word for word

Nevro integration risks; competitive pressures in musculoskeletal technology; regulatory changes

“Nevro performed as expected as we continue to diligently work through the integration; forward-looking statements mention risks related to competition and regulation” · word for word

Integration execution risk

“Acquisition-related costs increased by $5.3 million, or 503.3%, primarily driven by the change in the fair value of business acquisition liabilities.” · word for word

Restructuring costs

“Restructuring costs increased by $5.2 million due to higher employee termination benefit expenses from the 2024 Synergy Plan and the 2025 Strategic Integration Plan.”

Controlled Company Governance

“We are a 'controlled company' as set forth in NYSE Rule 303A.00 because more than 50% of the voting power of our common stock is held by David C. Paul, our Chairman of the Board of Directors and Executive Chairman.” · word for word

Key Person / Founder Concentration

“David C. Paul... 22,258,997 Class B shares (99.2% of Class B) and 772,917 Class A shares, representing 66.2% of combined voting power.”

CEO Transition Risk

“Mr. Scavilla served as Chief Executive Officer until his resignation effective July 18, 2025.” · word for word

Board departure could signal governance concerns, but no disagreement stated.

“Resignation effective immediately; no disagreement with company.”

Integration risk from Nevro acquisition

“Nevro contributed $99.7M in Q4 sales; integration appears successful but ongoing.”

Healthcare consolidation pricing pressure

“Consolidation in the healthcare industry could lead to demands for price concessions or to the exclusion of some suppliers from certain of our markets, which could have an adverse effect on our business, results of operations or financial condition.” · word for word

Inventory obsolescence risk

“In the event that a substantial portion of our inventory becomes obsolete, it could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with the inventory impairment charges and costs required to replace such inventory.” · word for word

Cybersecurity and data privacy risk

“If our information technology systems are compromised, we could be subject to fines, damages, litigation and enforcement actions and we could lose PII, PHI, trade secrets or other confidential information, the occurrence of which could harm our reputation, business, results of operations and financial condition.” · word for word

IONM services regulatory and billing risk

“These measures could limit the amount we can charge and recover for the IONM services we furnish where we have not contracted with the patient’s insurer, which could negatively impact the profitability of our IONM services business.” · word for word

Integration risks from NuVasive and Nevro acquisitions.

“continued success in the integration of the NuVasive and Nevro acquisitions” · word for word

Integration risk from NuVasive merger and Nevro acquisition

“Synergy capture and integration strategy highlighted; Nevro exceeding expectations”

Integration risk from Nevro and NuVasive acquisitions

“The Company recorded restructuring costs of $13.9M (9M 2025) related to integration plans.”

High accounts receivable and inventory levels

“Accounts receivable $619.1M and inventories $771.5M as of Sep 2025.”